Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...

It is the first approval for Beyfortus (nirsevimab) by any regulatory authority. AZ's Synagis (palivizumab) is currently the only approved drug in Europe to provide passive prophylaxis against RSV ...

Dr. Patrick Hemmons travelled to Seattle to get an RSV shot for his daughter. He says he hopes to see nirsevimab become more easily accessible across the country.

The French drugmaker said it had entered a mandate with an “investment service provider”, with the purchase occurring between ...

L'Oréal is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.

AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.

The panel also said Beyfortus (nirsevimab) could be an option for some older babies at increased risk of severe illness caused by RSV as it recommended that the shot be used in the US Vaccines for ...

The pioneering beyfortus provides a solution to decrease RSV cases. It bolsters passive immunity through a single-dose monoclonal antibody, nirsevimab, which targets and neutralizes the ...

Sanofi and partner AstraZeneca’s AZN RSV antibody Beyfortus (nirsevimab) recorded sales of €841 million in the fourth quarter, up 107% year over year, driven by higher sales in the United ...